We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Kit Distinguishes Between HSV-1 and HSV-2 in Vaginal Specimens

By LabMedica International staff writers
Posted on 01 Jun 2010
Qualitative detection of Herpes simplex virus (HSV) types 1 or 2 is based on the polymerase chain reaction (PCR). More...
Results are available in approximately four hours.

The HSV 1&2 kit utilizes MultiCode-RTx technology based on the company's novel synthetic DNA base pair (nucleotide): isoC:isoG. Not only are the isoC and isoG specific to each other, they are recognized by the enzyme used for PCR. This probe free chemistry provides significant ease-of-use and workflow advantages.

MultiCode-RTx uses PCR to amplify and then detect target DNA sequences. If a specific target sequence is present, PCR amplification will occur. During the amplification process, MultiCode directs the PCR enzyme to insert a fluorescence quencher directly opposite a reporter dye resulting in a decrease of fluorescence with every PCR cycle. The decrease is easily monitored by real-time PCR instruments.

EraGen Biosciences Inc. (Madison, WI, USA) announced that the U.S. Food and Drug Administration (FDA; Silver Springs, MD, USA) has granted 510(k) market clearance for the company's MultiCode-RTx HSV 1&2 Kit. The assay is not intended to be used for male penile specimens, for prenatal screening, or for females under the age of 18 years.

"EraGen's HSV 1&2 kit is the first FDA-cleared, molecular test for the Herpes simplex virus. It has considerable advantages over the traditional testing methodologies used today for the detection and typing of the virus in symptomatic women,” said Irene Hrusovsky, M.D., president and chief executive of EraGen.

Herpes simplex viruses cause oral and genital herpes infections. In immunocompromised individuals and infants, they can cause central nervous system disorders, blindness, liver disease, brain infections, and other illnesses.

EraGen Biosciences develops, manufactures, and markets innovative molecular diagnostic products. The company's in-market and pipeline products, based on MultiCode platform chemistry, are the next generation of DNA- and RNA-based testing for the early detection of infectious diseases and genetic conditions.

Related Links:
EraGen Biosciences Inc.
U.S. Food and Drug Administration


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Serological Pipet Controller
PIPETBOY GENIUS
New
Rapid Test Reader
DIA5000
New
Specimen Radiography System
TrueView 200 Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.